Abdera Therapeutics
PrivateLast Round
Series B
Apr 4, 2023
Total Funding Raised
$180.78M
Company Overview
Abdera Therapeutics is a biotechnology company that develops a precision oncology platform for targeted alpha radiation therapies aimed at patients with relapsed, refractory, and metastatic cancers.
Sector
Healthcare & Life Sciences
Verticals
Biotechnology, Drug Discovery, Precision Medicine, Clinical Trials
Business Model
B2B
Customer Profile
Services & Consulting
AI Layer
Non-AI
Keywords
Historical Pricing
Historical view of private secondary pricing and transaction trends.
Abdera Therapeutics Comparables
Compare Abdera Therapeutics with similar companies based on industry and business-model similarity.
| Company | Similarity | Market Cap |
|---|---|---|
| Alpha-9 Oncology | 87% | |
| Radionetics Oncology | 87% | |
| Ratio Therapeutics Inc. | 84% |
Abdera Therapeutics Funding Rounds
Historical fundraising activity
| Round | Date | Amount Raised | Valuation | Investors | Sources |
|---|---|---|---|---|---|
| Series B | Apr 4, 2023 | ||||
| Seed | Jan 14, 2021 |
Key People
Founding team and executive leadership
Abdera Therapeutics Investors
Notable investors and investment history
| Investor | Rounds |
|---|---|
| Amplitude Ventures | Series B, Series A |
| Versant Ventures | Series B, Series A |
| Viking Global Investors | Series B |
| venBio | Series B |
| Qiming | Series B |
| Northview LifeSciences | Series A, Series B |
| RTW Investments | Series B |
Market signals
Structured signals derived from secondary market and firmographic data.
- Jan 13, 2026
Presenting at the 44th Annual J.P. Morgan Healthcare Conference.
- Aug 26, 2025
Initial Phase 1 data for ABD-147 presented at IASLC 2025.
Abdera Therapeutics Filings
Explore SEC and related filing metadata, where available.
| Type | Date | Amount Offered | Amount Sold | Filing | Pages | Download |
|---|
Filing documents are not displayed on this public page. Request access to learn about available coverage.
Request accessFrequently Asked Questions
Common questions about Abdera Therapeutics's valuation, stock price, and market status.
Is Abdera Therapeutics a public or private company?
Abdera Therapeutics is a private company.
What is the current stock price of Abdera Therapeutics?
Abdera Therapeutics is a private company with no public stock price. No recent secondary market data is available.
How much is Abdera Therapeutics worth (valuation)?
Valuation information for Abdera Therapeutics is not publicly available.
Can I buy Abdera Therapeutics stock?
Abdera Therapeutics shares may be available on secondary markets subject to transfer restrictions. Caplight facilitates secondary market transactions for accredited investors. Visit https://www.caplight.com to learn more.
When was Abdera Therapeutics's last funding round?
Abdera Therapeutics's most recent funding round was Series B on April 20, 2023.
Who are the main investors in Abdera Therapeutics?
Key investors in Abdera Therapeutics include Amplitude Ventures, Versant Ventures.
Will Abdera Therapeutics IPO soon?
No public IPO plans have been announced for Abdera Therapeutics.
How can I track Abdera Therapeutics secondary market activity?
Caplight tracks bids, offers, and trades for private companies. Visit https://www.caplight.com to monitor Abdera Therapeutics's secondary market activity and sign up for updates.